Every 10-Q that PERRIGO COMPANY PLC (PRGO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PRGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRGO filings page.
Perrigo Company plc reported a sharp first‑quarter loss driven by large non‑cash impairments and restructuring costs. Net sales were $969.2 million, down from $1,043.9 million a year earlier, as Self Care, Specialty Care and All Other all declined modestly while Infant Formula was roughly flat.
The company recorded $330.8 million of goodwill impairments tied to Women’s Health, Infant Formula and Oral Care reporting units, plus $75.1 million of restructuring charges, turning operating income of $46.9 million last year into an operating loss of $372.3 million. Net loss from continuing and discontinued operations widened to $398.6 million, or $2.87 per diluted share, compared with a $6.4 million loss, or $0.05 per share, in the prior‑year period.
Cash used in operating activities was $113.6 million, and cash and cash equivalents fell to $357.2 million from $531.6 million at year‑end 2025. Total borrowings were $3,632.5 million, including $970.0 million of term loans and $2,262.2 million of notes and bonds. Perrigo also completed an amended credit agreement, drew $427.6 million on its revolver to repay Term Loan A, and completed the sale of its Dermacosmetics business after quarter‑end for up to €332.6 million in consideration.
Perrigo Company plc reported third-quarter 2025 results. Net sales were $1,043.3 million versus $1,087.5 million a year ago, while operating income was $72.6 million versus $80.4 million. Net income was $7.5 million compared with a loss of $21.0 million in the prior-year quarter. Interest expense improved to $40.6 million from $57.6 million.
Year to date, sales were $3,143.5 million versus $3,235.1 million, with operating income of $164.9 million (versus a slight loss last year) and a net loss of $7.3 million (versus $127.3 million). Cash from operating activities was $63.1 million. Cash stood at $432.1 million and long‑term debt at $3,608.1 million. Inventories were $1,227.0 million.
The company agreed to sell its Dermacosmetics branded business for up to €327 million, including €300 million upfront and up to €27 million in earn‑outs, subject to regulatory and works council approvals, with closing expected in the first quarter of 2026. Related assets and liabilities held for sale were $280.5 million and $37.4 million, respectively. Shares outstanding were 137,624,009 as of October 31, 2025.
Perrigo Company plc — Quarterly highlights (Q2 ended June 28, 2025)
Net sales of $1,056.3M for the quarter and $2,100.2M for six months, down vs. prior year. Gross profit for the quarter was $362.9M. Operating income improved to $45.4M (vs. a loss of $26.5M a year ago); continuing operations reported a small loss of $0.5M for the quarter. Discontinued operations produced a loss of $7.9M, and diluted EPS was a loss of $0.06 for the quarter and $0.10 for six months.
Balance sheet and cash: cash and equivalents $454.2M (down $104.6M YTD); inventories increased to $1,215.5M. Total assets $10,094.1M; total liabilities $5,621.8M. Total borrowings outstanding $3,651.9M. Notable items: sale of Richard Bittner Business for $14.4M (pre-tax loss $1.6M); Prevacid impairment $1.5M; litigation accrual for price-fixing $30.0M with a 50% recovery receivable under indemnity (Altaris cap $50.0M). Foreign currency translation increased comprehensive income, producing comprehensive income of $137.0M for the quarter.